BioAffinity Technologies reports Q2 EPS (19c), consensus (17c)

Reports Q2 revenue $2.4M, consensus $2.45M. “We are encouraged by the momentum we’ve achieved in the second quarter, with CyPath Lung sales growing 217% over the previous quarter and exceeding our initial forecasts,” bioAffinity President and Chief Executive Officer Maria Zannes said. “This growth underscores the increasing recognition of the role CyPath(R) Lung can play in the early detection of lung cancer, a disease where early diagnosis can significantly improve patient outcomes. As we expand our reach beyond Texas, the positive reception from physicians across multiple states reinforces our belief that CyPath Lung will have a significant impact in lung cancer diagnostics, a U.S. market projected to reach $4.7 billion by 2030.”